| 12502376 |
Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) |
Michael P. Clark, Simon Giroux, Philip Collier, Qingfu Tang, Nathan D. Waal +14 more |
2025-12-23 |
|
| 12421249 |
Inhibitors of APOL1 and methods of using same |
Jun Myun Ahn, Samantha ANGLE, Jingrong Cao, John Cochran, Jon Come +10 more |
2025-09-23 |
|
| 12398119 |
Piperazine azaspiro derivatives |
Lei Zhang, Erik Alphie LaChapelle, Christopher Ryan Butler, Natasha Mariam Kablaoui, Laura Ann McAllister +3 more |
2025-08-26 |
|
| 12331057 |
Modulators of alpha-1 antitrypsin |
Upul K. Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael Boyd, Michael P. Clark +39 more |
2025-06-17 |
|
| 12060346 |
Inhibitors of APOL1 and methods of using same |
Jingrong Cao, Jon Come, Leslie Dakin, Francois Denis, Warren Dorsch +16 more |
2024-08-13 |
$623,134,000 |
| 11964961 |
Heteroaromatic compounds and their use as dopamine D1 ligands |
Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green +6 more |
2024-04-23 |
$398,665,000 |
| 11905284 |
5,7-dihydro-pyrrolo-pyridine derivatives |
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Matthew Frank Brown, Laura Ann McAllister +2 more |
2024-02-20 |
$283,621,000 |
| 11884672 |
Modulators of alpha-1 antitrypsin |
Upul K. Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael Boyd, Michael P. Clark +39 more |
2024-01-30 |
$648,597,000 |
| 11866446 |
Inhibitors of APOL1 and methods of using same |
Jun Myun Ahn, Samantha ANGLE, Jingrong Cao, John Cochran, Jon Come +10 more |
2024-01-09 |
$332,357,000 |
| 11623924 |
Modulators of alpha-1 antitrypsin |
Upul K. Bandarage, Cavan McKeon Bligh, Michael Boyd, Diane Boucher, Veronique Damagnez +31 more |
2023-04-11 |
$612,568,000 |
| 11618746 |
Inhibitors of APOL1 and methods of using same |
Jingrong Cao, Jon Come, Leslie Dakin, Francois Denis, Warren Dorsch +16 more |
2023-04-04 |
$604,201,000 |
| 11524954 |
Piperazine azaspiro derivatives |
Lei Zhang, Erik Alphie LaChapelle, Christopher Ryan Butler, Natasha Mariam Kablaoui, Laura Ann McAllister +3 more |
2022-12-13 |
$1,137,745,000 |
| 11312713 |
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors |
Thomas Allen Chappie, Jinshan Chen, Jotham Wadsworth Coe, Karen Coffman, Paul Galatsis +14 more |
2022-04-26 |
$777,515,000 |
| 11198692 |
Dihydro-pyrrolo-pyridine derivatives |
Elizabeth Mary Beck, Matthew Frank Brown, Christopher Ryan Butler, Adam Matthew Gilbert, Erik Alphie LaChapelle +3 more |
2021-12-14 |
$1,320,244,000 |
| 11014909 |
Heteroaromatic compounds and their use as dopamine D1 ligands |
Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green +6 more |
2021-05-25 |
$425,301,000 |
| 10858373 |
Heterocyclic spiro compounds as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Christopher John Helal, Steven Victor O'Neil, Patrick Robert Verhoest |
2020-12-08 |
$1,644,744,000 |
| 10723711 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Adam Matthew Gilbert, Christopher John Helal +6 more |
2020-07-28 |
$482,302,000 |
| 10696658 |
Heteroaromatic compounds and their use as dopamine D1 ligands |
Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green +6 more |
2020-06-30 |
$597,435,000 |
| 10626125 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Christopher John Helal, Steven Victor O'Neil, Patrick Robert Verhoest |
2020-04-21 |
$1,173,015,000 |
| 10604519 |
5,7-dihydro-pyrrolo-pyridine derivatives |
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Matthew Frank Brown, Laura Ann McAllister +2 more |
2020-03-31 |
$1,088,300,000 |
| 10428034 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Adam Matthew Gilbert, Christopher John Helal +6 more |
2019-10-01 |
$298,967,000 |
| 10421744 |
Heteroaromatic compounds and their use as dopamine D1 ligands |
Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green +6 more |
2019-09-24 |
$287,330,000 |
| 10329308 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Christopher John Helal, Steven Victor O'Neil, Patrick Robert Verhoest |
2019-06-25 |
$317,230,000 |
| 10316021 |
Heteroarylphenoxy benzamide kappa opioid ligands |
Natasha Mariam Kablaoui, Michael Eric Green, Justin Ian Montgomery, Patrick Robert Verhoest, Gregory Wayne Kauffman +5 more |
2019-06-11 |
$297,650,000 |
| 10253042 |
N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides |
Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill |
2019-04-09 |
$284,175,000 |
